Pharmaceutical research and development is organized around prioritized investments, delivering on assets with the greatest return of investments. Linear sequencing of trials and financial risks are determinants of speed in an enterprise. There is less flexibility in leveraging expertise around priorities that are thrust on the system by external forces.
This commentary provides an insight into enabling warp speed using a hypervelocity mindset for mobilizing resources and scientific creativity for accelerated timelines in response to pandemics.
Read the full commentary here: